While patients with EGFR- and ALK-mutant lung cancer do often respond to EGFR and ALK inhibitors, these responses are temporary, as acquired resistance inevitably develops (Tang et al., 2013; Wilson et al., 2015). The gene discussed is EGFR; the disease is lung cancer.